Press Releases

Investor Alerts

Sep 3, 2019

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
Aug 22, 2019

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Jul 8, 2019

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial
May 29, 2019

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --
Apr 24, 2019

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019

Show per page